<DOC>
	<DOC>NCT01948570</DOC>
	<brief_summary>Primary end point of the study is the clinical and non-invasive instrumental evaluation of the activity of P-3075 cream on subjects with acne: 20 subjects with a mild/moderate grade and 20 subjects with a moderately severe/severe grade, according to Cunliffe' classification. Secondary end-points are the cosmetic acceptability and efficacy evaluation by the volunteers and the local tolerability assessed by the investigator and the subjects.</brief_summary>
	<brief_title>Clinical Study for the Evaluation of P-3075 Cream on Acne Treatment</brief_title>
	<detailed_description>This is an open controlled clinical trial. The product will be applied for a period of 4 weeks and 3 visits will be performed: a baseline visit (T0), an intermediate visit after 2 weeks (T2) and a final visit after 4 week-treatment (T4). The subjects will be enrolled and divided in 2 groups according to their acne grade (20 subjects with mild/moderate grade and 20 subjects with moderately severe/severe), a concomitant therapy is allowed only for volunteers with acne moderately severe/severe. Each volunteer, fulfilling the inclusion criteria, will perform a cosmetic treatment with the study product on all the face, for 4 weeks. A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0). Group 2 will continue also the standardised treatment with topical or systemic retinoids, benzoyl peroxide, clindamycin or AHA until the end of the study.</detailed_description>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>both genders; age &gt; 16 years old; acne of mild/moderate grade, not in therapy (GROUP 1); acne of moderately severe/severe grade, in therapy with topical or systemic retinoids, benzoyl peroxide, clindamycin or AHA (GROUP 2); accepting to follow the instructions received by the investigator; available to return to the study centre at the protocol visits; accepting to not change the normal life habits regarding: food, physical activity, face cleansing; accepting not to receive any other drug/cosmetic treatment able to interfere with the study results; accepting to sign the informed consent form (under 18 years the signature of both parents is required). Pregnancy (only for female subjects) for subjects belonging to Group 2, a control pregnancy test could be required at T2 and T4 in case of assumption of an antiacne drug with potential teratogenic effects; these subjects must confirm to use adequate contraceptive precautions in order to avoid pregnancies; lactation (only for female subjects); subjects whose insufficient adhesion to the study protocol is expected; subjects who changed the antiacne therapy during the 2 months prior to the study inclusion; concomitant participation in other studies or in the last 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>acne,comedones, oily skin</keyword>
</DOC>